

103^D CONGRESS
1ST SESSION

H. R. 1709

To amend the Federal Food, Drug, and Cosmetic Act to establish provisions regarding the composition and labeling of dietary supplements.

IN THE HOUSE OF REPRESENTATIVES

APRIL 7, 1993

Mr. RICHARDSON (for himself, Mr. INHOFE, Mr. TOWNS, Mr. BOEHLERT, Mr. SCHIFF, Mr. FROST, Ms. NORTON, Mr. BOUCHER, Mr. BOEHNER, Mr. PETERSON of Minnesota, Ms. PELOSI, Mr. HALL of Texas, Mr. UPTON, and Mr. PALLONE) introduced the following bill; which was referred to the Committee on Energy and Commerce

JUNE 8, 1993

Additional sponsors: Mr. LAROCO, Mr. OLVER, Mr. KREIDLER, Mr. INGLIS of South Carolina, Mr. DOOLITTLE, Mr. PASTOR, Mr. BURTON of Indiana, Mr. HOCHBRUECKNER, Mr. PARKER, Mr. SENSENBRENNER, Mr. SPENCE, Ms. VELÁZQUEZ, Mrs. UNSOELD, and Mr. INSLEE

JULY 28, 1993

Additional sponsors: Mr. SKAGGS, Mr. JEFFERSON, Mr. LEWIS of Florida, Mr. COMBEST, Mr. HERGER, Mr. ORTON, Mr. MANZULLO, Mr. RANGEL, Mr. SHAYS, Mr. DEFazio, Mr. BARCIA of Michigan, Mr. SWETT, Mr. ZELIFF, Mr. CANADY, Mr. LIPINSKI, Mr. CALLAHAN, Mr. FRANK of Massachusetts, Mr. FARR of California, Mr. NEAL of Massachusetts, Mr. TAUZIN, Mr. MEEHAN, Mr. BEVILL, and Mr. MCHALE

AUGUST 23, 1993

Additional sponsors: Mr. BLUTE, Mr. COX, Mr. YATES, Mr. HASTERT, and Mr. KINGSTON

SEPTEMBER 9, 1993

Additional sponsors: Mr. REYNOLDS, Mr. APPLGATE, Mr. LINDER, Mrs. KENNELLY, Mr. STEARNS, Mr. MURPHY, Ms. FURSE, Mr. KNOLLENBERG, Mr. MICA, Mr. SARPALIUS, Mrs. FOWLER, Mr. ROTH, Mr. THOMAS of Wyoming, Mr. BONILLA, Ms. WOOLSEY, Mr. GREENWOOD, Mr. COYNE, Mr. DEAL, Mr. KING, Ms. SHEPHERD, Mr. BARLOW, and Ms. ESHOO

OCTOBER 7, 1993

Additional sponsors: Mr. ALLARD, Mr. REGULA, Mr. GOODLATTE, Ms. MOL-

INARI, Mr. CONDIT, Mr. SCHAEFER, Mr. HAMBURG, Mr. CAMP, Mr. ARMEY, Mr. BAKER of California, Mr. DICKEY, Mr. BILBRAY, Mr. MCCOLLUM, Mr. MCCRERY, Mr. TALENT, Mr. MACHTLEY, Mrs. VUCANOVICH, Mr. CLEMENT, Mr. JACOBS, Mr. LEWIS of Georgia, Mr. BROOKS, Mr. KOPETSKI, Mr. GORDON, Mr. PORTMAN, Mr. BROWN of Ohio, Mr. MILLER of Florida, Mr. BROWN of California, Mr. HALL of Ohio, Mr. HINCHEY, Mr. DARDEN, Mr. KILDEE, Mr. KASICH, Mr. MCINNIS, Mr. DORNAN, Mr. FRANKS of Connecticut, Ms. DANNER, Mr. FISH, Ms. MCKINNEY, Mr. REED, Mr. DIAZ-BALART, Mr. DEUTSCH, Mr. ROYCE, Ms. KAPTUR, Mr. GILMAN, Mr. EWING, Mr. SHARP, Ms. DUNN, Mr. LEVY, Mr. GUTIERREZ, Mr. FAWELL, Mr. CALVERT, Mr. DE LA GARZA, Mr. ANDREWS of New Jersey, Mr. GEJDENSON, Mr. HASTINGS, Mr. TAYLOR of Mississippi, Mr. QUILLEN, Ms. BYRNE, Mr. MONTGOMERY, Mr. JOHNSON of Georgia, and Mr. WASHINGTON

A BILL

To amend the Federal Food, Drug, and Cosmetic Act to establish provisions regarding the composition and labeling of dietary supplements.

1 *Be it enacted by the Senate and House of Representa-*
 2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE AND REFERENCE.**

4 (a) SHORT TITLE.—This Act may be cited as the
 5 “Dietary Supplement Health and Education Act of 1993”.

6 (b) REFERENCE.—Whenever in this Act (other than
 7 section 7) an amendment or repeal is expressed in terms
 8 of an amendment to, or repeal of, a section or other provi-
 9 sion, the reference shall be considered to be made to a
 10 section or other provision of the Federal Food, Drug, and
 11 Cosmetic Act.

1 **SEC. 2. DEFINITIONS.**

2 (a) DIETARY SUPPLEMENT.—Section 201 (21 U.S.C.
3 321) is amended by adding at the end the following new
4 paragraph:

5 “(gg) The term ‘dietary supplement’ means a food
6 for special dietary use, as defined in section 411(c)(3),
7 that—

8 “(1) includes one or more—

9 “(A) vitamins;

10 “(B) minerals;

11 “(C) herbs;

12 “(D) amino acids; or

13 “(E) other ingredients for use by man to
14 supplement the diet by increasing the total die-
15 tary intake, including a concentrate or extract
16 of any article listed in this paragraph; and

17 “(2) is intended for use in tablet, capsule, pow-
18 der, softgel, or any other form (including liquid
19 form) that is not represented for use as conventional
20 food or as a sole item of a meal or of the diet.”.

21 (b) FOOD ADDITIVE.—Section 201(s) (21 U.S.C.
22 321(s)) is amended—

23 (1) by striking out the period at the end of sub-
24 paragraph (5) and inserting in lieu thereof “; or”;
25 and

1 (2) by adding after subparagraph (5) the fol-
2 lowing:

3 “(6) any dietary ingredients of the kind speci-
4 fied in paragraph (gg)(1) in, or intended for use in,
5 a dietary supplement.

6 For purposes of subparagraph (6) the term ‘dietary ingre-
7 dient’ means an ingredient that is in, or intended for use
8 in, a dietary supplement.”.

9 **SEC. 3. DIETARY SUPPLEMENT LABELING AND COMPOSI-**
10 **TION.**

11 (a) ADULTERATION.—Section 402 (21 U.S.C. 342)
12 is amended by adding at the end the following:

13 “(f) If it is a dietary supplement and—

14 “(1) it contains an unsafe dietary ingredient
15 which is a substance that is intended to be
16 consumed for its dietary properties but which the
17 Secretary has found through rulemaking to present
18 a substantial and unreasonable risk of illness or in-
19 jury; or

20 “(2) it contains a dietary ingredient that has
21 not been adequately substantiated for safety by the
22 person identified under section 403(e)(1) or by the
23 raw material manufacturer through—

24 “(A) evidence of a history of safe use (as
25 part of any prior intended use) and the absence

1 of substantial information that brings the safety
2 of the ingredient into question; or

3 “(B) by well-designed scientific studies
4 conducted in a manner that is consistent with
5 generally recognized scientific procedures and
6 principles; or

7 “(C) by other appropriate means.

8 A dietary ingredient that is found to be safe for use in
9 a dietary supplement or as a nutrient by the Secretary
10 or by the National Academy of Sciences through the estab-
11 lishment of a recommended dietary allowance or an esti-
12 mated safe and adequate dietary intake shall be deemed
13 to have met the requirements of this paragraph within the
14 scope of the determination by the Secretary or the Na-
15 tional Academy of Sciences.

16 “(g)(1) If it is a dietary supplement and the Sec-
17 retary was not notified, in accordance with regulations is-
18 sued under subparagraph (2), about a significant change
19 in the manufacturing practice which produced the supple-
20 ment or of potential problems of safety or contamination
21 affecting such practice.

22 “(2) The Secretary shall promulgate regulations
23 within 18 months of the date of the enactment of this sub-
24 paragraph to require notification to the Secretary by man-
25 ufacturers of raw materials utilized in dietary supplements

1 of significant changes in manufacturing practices of such
2 materials or of any potential problems of safety or con-
3 tamination arising from any such changes to ensure the
4 safety of such materials.

5 “(3) Subparagraphs (1) and (2) apply only to manu-
6 facturing changes that are substantial and have been
7 shown to present adverse safety consequences. These sec-
8 tions do not apply to routine changes in the formulating
9 and manufacturing of dietary supplements by dietary sup-
10 plement manufacturers that utilize good manufacturing
11 practices.”.

12 (b) MISBRANDING.—Section 403 (21 U.S.C. 343) is
13 amended by adding at the end the following:

14 “(s) If it is a dietary supplement and—

15 “(1) its label fails to list the name and quantity
16 or proportion of each dietary ingredient included in
17 section 201(gg), except that proprietary blends of in-
18 gredients may declare the quantity of the total
19 blend;

20 “(2) its label fails to identify the product as a
21 supplement, as a supplement modified with the
22 name of the ingredient of the kind specified in sec-
23 tion 201(gg)(1), or as a dietary supplement;

24 “(3) it contains an ingredient of the kind speci-
25 fied in section 201(gg)(1)(C) and the labeling fails

1 to identify the part of the plant from which the in-
2 gredient is derived;

3 “(4) if it purports to be or is represented as a
4 dietary supplement the name of which is listed in a
5 compendium for foods recognized in regulations is-
6 sued by the Secretary and its composition or
7 strength differs from, or its quality or purity (in-
8 cluding tablet or capsule disintegration or dissolu-
9 tion) falls below, the standards set forth in such
10 compendium unless such difference in composition,
11 strength, quality, or purity from the applicable com-
12 pendium standards is plainly stated on the label; or

13 “(5) it is not subject to subparagraph (4) and
14 its composition or strength differs from, or its purity
15 or quality (including tablet or capsule disintegration
16 or dissolution) falls below, that which it purports or
17 is represented to have.

18 Subparagraph (4) is not to be construed as prohibiting
19 a dietary supplement from representing that it meets U.S.
20 Pharmacopeia standards for dietary supplements if it
21 meets such standards. Such a supplement shall not be
22 deemed a drug because of such a representation.”.

23 (c) COMPOSITIONAL LIMITS.—Section 411 (21
24 U.S.C. 350) is amended by adding at the end the follow-
25 ing:

1 “(d)(1) Except as provided in paragraph (2), the Sec-
2 retary may not—

3 “(A) establish under section 201(n), 401, or
4 403 maximum limits on the potency of any dietary
5 supplement or any dietary ingredient of the kind
6 specified in section 201(gg);

7 “(B) classify any dietary supplement or any in-
8 gredient of the kind specified in section 201(gg) as
9 a drug solely because it exceeds the level of potency
10 that the Secretary determines is nutritionally ration-
11 al or useful; or

12 “(C) limit, under section 201(n), 401, or 403,
13 in a dietary supplement the combination or number
14 of ingredients of the kind specified in section
15 201(gg).

16 “(2) Paragraph (1) does not apply in the case of a
17 dietary supplement represented (other than in conformity
18 with section 403(r)(5)(D)) for use by individuals in the
19 treatment or management of specific diseases or disorders,
20 by children, or by pregnant or lactating women. For pur-
21 poses of this paragraph, the term ‘children’ means individ-
22 uals who are under the age of 12 years.”.

23 **SEC. 4. CLAIMS.**

24 Section 403(r)(5)(D) (21 U.S.C. 343(r)(5)(D)) is
25 amended to read as follows:

1 “(D)(i) A subparagraph (1)(B) claim made with re-
2 spect to a dietary supplement shall not be subject to sub-
3 paragraph (3).

4 “(ii) Labeling of a dietary supplement may character-
5 ize the relationship between the supplement and a disease
6 or other condition of the body if—

7 “(I) the supplement contains one or more nutri-
8 ents for which a claim of the type described in sub-
9 paragraph (1)(B) has been authorized by the Sec-
10 retary pursuant to subparagraph (3)(B) and such
11 characterization is consistent with the claim author-
12 ized by the Secretary, unless the Secretary deter-
13 mines, through rulemaking based upon the totality
14 of publicly available scientific evidence, that con-
15 sumption of the nutrient in a dietary supplement
16 would not tend to reduce the risk of disease or other
17 health-related condition in a manner similar to the
18 consumption of such nutrient in conventional foods;
19 or

20 “(II) such characterization accurately rep-
21 resents the current state of scientific evidence con-
22 cerning the relationship between the supplement or
23 dietary ingredient of the supplement and a disease
24 or other health-related condition, taking into account
25 the totality of scientific evidence (including evidence

1 from well-designed studies conducted in a manner
2 consistent with generally recognized scientific prin-
3 ciples).

4 This clause does not prohibit the labeling of a dietary sup-
5 plement from providing truthful and non-misleading infor-
6 mation, measured by the standard set forth in subclause
7 (II), concerning its vitamin, mineral, or other dietary
8 properties, including nutritional information about the
9 manner in which those dietary properties affect physio-
10 logical processes of the body or prevent or repair damage
11 caused by diet or other environmental factors and does
12 not authorize the Secretary to establish a prior restraint
13 on the use of any labeling that is subject to subclause (II).

14 “(iii) At least 30 days before the introduction into
15 interstate commerce of any label, consumer package, or
16 literature in the package containing a claim described in
17 subclause (ii), or before the making of such a claim
18 through any other means, a person responsible for market-
19 ing the dietary supplement to which such claim refers shall
20 provide notification to the Secretary of the wording of
21 such claim if such claim has not previously been made for
22 such dietary supplement by such person. Documentation
23 that is intended to support such claim may be submitted
24 with such notice. The Secretary may not impose any addi-

1 tional pre-market requirement, including requirements or
2 requests for further documentation.”.

3 **SEC. 5. DIETARY INTAKE STANDARDS.**

4 (a) NUTRITION INFORMATION.—Section 403(q)(1)
5 (21 U.S.C. 343(q)(1)) is amended by striking the period
6 at the end of subparagraph (E) and inserting in lieu there-
7 of “, or” and by adding after that subparagraph the fol-
8 lowing:

9 “(F) a declaration of the percent of a daily ref-
10 erence amount for each nutrient specified in sub-
11 paragraphs (D) and (E), stated as a ‘Percent Daily
12 Value’ provided by a serving of that food.”.

13 (b) REGULATIONS.—

14 (1) IN GENERAL.—

15 (A) DAILY VALUE.—Subject to subpara-
16 graph (B), the Secretary of Health and Human
17 Services shall, by regulation, determine, based
18 on the dietary guidance provided by the Depart-
19 ment of Agriculture, the Department of Health
20 and Human Services, the Centers for Disease
21 Control, the National Institutes of Health, and
22 other authoritative public health organizations,
23 a daily value for each nutrient specified in sub-
24 paragraphs (1)(D) and (1)(E) of section 403(q)
25 of the Federal Food, Drug, and Cosmetic Act

1 which shall reflect the daily intake of each such
2 nutrient that will promote optimal health and
3 minimize the risk of disease or other health-re-
4 lated condition.

5 (B) LIMITATION.—The daily value deter-
6 mined by the Secretary under subparagraph (A)
7 shall be no less than the Recommended Daily
8 Allowances established by the Food and Nutri-
9 tion Board of the National Academy of Sciences
10 for the age and sex group most at risk of nutri-
11 tional deficiencies of any particular nutrient.

12 (2) TIMING.—Except as provided in paragraph
13 (4), the Secretary of Health and Human Services
14 shall issue proposed regulations under paragraph (1)
15 no later than 12 months from the date of the enact-
16 ment of this Act and shall issue final regulations no
17 later than 24 months from such date.

18 (3) PENDING DAILY VALUES.—Pending the is-
19 suance of final regulations under paragraph (1), the
20 daily values for the nutrients declared under section
21 403(q)(1)(F) of the Federal Food, Drug, and Cos-
22 metic Act (21 U.S.C. 343(q)(1)(F)) shall be those
23 specified in sections 101.9(8) and 101.9(9) of regu-
24 lations published in title 21 of the Code of Federal

1 Regulations, as in effect on the date of the enact-
2 ment of this Act.

3 (4) ASSISTANCE.—To assist the Secretary of
4 Health and Human Services in issuing regulations
5 under paragraph (1), the Director of the Congres-
6 sional Research Office, in consultation with the Di-
7 rector of the Office of Technology Assessment, shall
8 arrange for that office to review existing scientific
9 data and conduct one or more studies, if necessary,
10 to be completed no later than 9 months from the
11 date of the enactment of this Act, to determine what
12 amount of each nutrient specified in subparagraphs
13 (1)(D) and (1)(E) of section 403(q) of the Federal
14 Food, Drug, and Cosmetic Act (21 U.S.C. 343(q))
15 would be provided by the diets recommended by the
16 Department of Agriculture, the Department of
17 Health and Human Services, the Centers for Dis-
18 ease Control, the National Institutes of Health, and
19 other authoritative public health organizations to
20 minimize the risk of disease and other health-related
21 conditions and to promote optimal health. If the Of-
22 fice of Technology Assessment does not complete the
23 studies determined to be necessary within 9 months
24 from the date of the enactment of this Act, the time
25 prescribed by paragraph (2) for the issuance of pro-

1 posed and final regulations shall be extended by a
2 period equal to the additional time required by such
3 Office to complete such studies.

4 **SEC. 6. APPEAL.**

5 Section 411 (21 U.S.C. 350), as amended by section
6 3(c), is amended by adding at the end the following:

7 “(e)(1) If the Secretary asserts that a dietary supple-
8 ment is in violation of any provision of this Act, whether
9 the assertion is made in a warning letter issued by an offi-
10 cer or employee of the Department of Health and Human
11 Services or in any other manner, the manufacturer, proc-
12 essor, packer, distributor, or retailer of the dietary supple-
13 ment or any other person to whom the assertion is ad-
14 dressed may, within 60 days, appeal to the Secretary or
15 to an officer or employee of the Department of Health and
16 Human Services assigned by the Secretary to hear such
17 an appeal showing that the assertion is incorrect and
18 should be withdrawn. During the 60-day period after such
19 assertion is made by the Secretary and during pendency
20 of such an appeal, the United States shall not initiate liti-
21 gation on the matter unless the Secretary concludes that
22 such litigation is required because of an imminent hazard
23 to health. If such an appeal is not resolved to the satisfac-
24 tion of the appellant, the appellant may—

1 “(A) bring an action in a United States district
2 court in any appropriate judicial district under sec-
3 tion 1391 of title 28, United States Code, to secure
4 a declaratory judgment in which all factual deter-
5 minations regarding the validity of the assertion in
6 question shall be made de novo; or

7 “(B) obtain any other means of judicial review
8 authorized by law.

9 The absence of an action described in subparagraph (A)
10 or (B) shall not establish any inference that an assertion
11 is valid.

12 “(2) The institution by the United States of a libel
13 of information to condemn a dietary supplement shall con-
14 stitute final agency action on the part of the Secretary.”.

15 **SEC. 7. OFFICE FOR DIETARY SUPPLEMENTS.**

16 (a) IN GENERAL.—Title IV of the Public Health
17 Service Act is amended by inserting after section 486 (42
18 U.S.C. 287c-3) the following:

19 “Subpart 4—Office for Dietary Supplements

20 **“SEC. 486E. OFFICE OF DIETARY SUPPLEMENTS.**

21 “(a) ESTABLISHMENT.—The Secretary shall estab-
22 lish an Office of Dietary Supplements within the National
23 Institutes of Health.

24 “(b) DUTIES.—The Office for Dietary Supplements
25 shall—

1 “(1) conduct and coordinate scientific research
2 within the National Institutes of Health relating to
3 dietary supplements and the extent to which the use
4 of dietary supplements can limit or reduce the risk
5 of diseases such as heart disease, cancer, birth de-
6 fects, osteoporosis, cataracts, or prostatism;

7 “(2) collect and compile the results of scientific
8 research relating to dietary supplements, including
9 scientific data from foreign sources or the Office of
10 Alternative Medical Practice;

11 “(3) serve as the principal advisor to the Sec-
12 retary and to the Assistant Secretary for Health,
13 and to provide advice to the Director of the National
14 Institutes of Health, the Director of the Centers for
15 Disease Control and Prevention, and the Commis-
16 sioner of Food and Drugs, on issues relating to die-
17 tary supplements including—

18 “(A) dietary intake regulations;

19 “(B) the safety of dietary supplements;

20 “(C) claims characterizing the relationship
21 between—

22 “(i) dietary supplements; and

23 “(ii) (I) prevention of disease or other
24 health-related conditions; and

25 “(II) maintenance of health; and

1 “(D) scientific issues arising in connection
2 with the labeling and composition of dietary
3 supplements;

4 “(4) compile a database of scientific research
5 on dietary supplements and individual nutrients;

6 “(5) coordinate funding relating to dietary sup-
7 plements for the National Institutes of Health;

8 “(6) explore more fully the potential role of die-
9 tary supplements as a significant part of the efforts
10 of the United States to improve health care; and

11 “(7) promote scientific study of the benefits of
12 dietary supplements in maintaining health and pre-
13 venting chronic disease and other health-related con-
14 ditions.

15 “(c) DEFINITION.—As used in this section, the term
16 ‘dietary supplement’ has the meaning given the term in
17 section 201(gg) of the Federal Food, Drug, and Cosmetic
18 Act (21 U.S.C. 321(gg)).

19 “(d) AUTHORIZATION OF APPROPRIATIONS.—There
20 are authorized to be appropriated to carry out this section
21 \$5,000,000 for fiscal year 1994 and such sums as may
22 be necessary for each subsequent fiscal year.”.

23 (b) CONFORMING AMENDMENT.—Section 401(b)(2)
24 of the Public Health Service Act (42 U.S.C. 281(b)(2))
25 is amended by adding at the end the following:

1 “(E) The Office for Dietary Supplements.”.

2 **SEC. 8. EFFECTIVE DATE.**

3 The amendments made by this Act shall take effect
4 on the date of the enactment of this Act, except that the
5 amendments made by section 3 shall take effect 18
6 months after such date with respect to products labeled
7 after such date.

○

HR 1709 SC6—2